Ascentage Pharma Group International (AAPG) Competitors

$19.57 -0.62 (-3.05%)

Closing price 03:58 PM Eastern

Extended Trading

$19.45 -0.12 (-0.59%)

As of 04:10 PM Eastern

AAPG vs. PCVX, KYMR, QGEN, TGTX, and MIRM

Should you buy Ascentage Pharma Group International stock or one of its competitors? MarketBeat compares Ascentage Pharma Group International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ascentage Pharma Group International include Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Qiagen (QGEN), TG Therapeutics (TGTX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

How does Ascentage Pharma Group International compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Vaxcyte has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vaxcyte had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 7 mentions for Vaxcyte and 4 mentions for Ascentage Pharma Group International. Vaxcyte's average media sentiment score of 0.99 beat Ascentage Pharma Group International's score of 0.72 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International's return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Ascentage Pharma Group International	N/A	N/A	N/A

Ascentage Pharma Group International has higher revenue and earnings than Vaxcyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Ascentage Pharma Group International	$574.12M	3.18	-$177.71M	N/A	N/A

Vaxcyte presently has a consensus price target of $86.00, indicating a potential upside of 64.15%. Ascentage Pharma Group International has a consensus price target of $46.67, indicating a potential upside of 138.52%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Summary

Ascentage Pharma Group International beats Vaxcyte on 7 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Kymera Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Ascentage Pharma Group International has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.06, suggesting that its share price is 106% more volatile than the broader market.

Ascentage Pharma Group International presently has a consensus price target of $46.67, indicating a potential upside of 138.52%. Kymera Therapeutics has a consensus price target of $118.10, indicating a potential upside of 43.65%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, research analysts plainly believe Ascentage Pharma Group International is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Kymera Therapeutics had 7 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 11 mentions for Kymera Therapeutics and 4 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.72 beat Kymera Therapeutics' score of 0.42 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascentage Pharma Group International has higher revenue and earnings than Kymera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$574.12M	3.18	-$177.71M	N/A	N/A
Kymera Therapeutics	$39.21M	172.47	-$311.35M	-$3.57	N/A

Ascentage Pharma Group International has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Ascentage Pharma Group International's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Summary

Ascentage Pharma Group International beats Kymera Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Qiagen?

Ascentage Pharma Group International (NASDAQ:AAPG) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Ascentage Pharma Group International has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ascentage Pharma Group International presently has a consensus target price of $46.67, indicating a potential upside of 138.52%. Qiagen has a consensus target price of $46.38, indicating a potential upside of 40.53%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Qiagen had 11 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 15 mentions for Qiagen and 4 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.72 beat Qiagen's score of 0.29 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$574.12M	3.18	-$177.71M	N/A	N/A
Qiagen	$2.09B	3.25	$424.88M	$1.91	17.28

Qiagen has a net margin of 19.16% compared to Ascentage Pharma Group International's net margin of 0.00%. Qiagen's return on equity of 14.40% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Qiagen	19.16%	14.40%	8.40%

Summary

Qiagen beats Ascentage Pharma Group International on 10 of the 15 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

58.6% of TG Therapeutics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.81	$447.18M	$2.86	13.81
Ascentage Pharma Group International	$574.12M	3.18	-$177.71M	N/A	N/A

TG Therapeutics currently has a consensus target price of $52.50, suggesting a potential upside of 32.91%. Ascentage Pharma Group International has a consensus target price of $46.67, suggesting a potential upside of 138.52%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

In the previous week, TG Therapeutics and TG Therapeutics both had 4 articles in the media. TG Therapeutics' average media sentiment score of 0.79 beat Ascentage Pharma Group International's score of 0.72 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 65.95% compared to Ascentage Pharma Group International's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Ascentage Pharma Group International	N/A	N/A	N/A

Summary

TG Therapeutics beats Ascentage Pharma Group International on 10 of the 14 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Mirum Pharmaceuticals has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.95	-$23.36M	-$13.61	N/A
Ascentage Pharma Group International	$574.12M	3.18	-$177.71M	N/A	N/A

In the previous week, Mirum Pharmaceuticals had 18 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 22 mentions for Mirum Pharmaceuticals and 4 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.72 beat Mirum Pharmaceuticals' score of 0.62 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals currently has a consensus target price of $136.42, suggesting a potential upside of 33.49%. Ascentage Pharma Group International has a consensus target price of $46.67, suggesting a potential upside of 138.52%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Ascentage Pharma Group International has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Ascentage Pharma Group International's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Ascentage Pharma Group International	N/A	N/A	N/A

Summary

Ascentage Pharma Group International beats Mirum Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AAPG vs. The Competition

Export

Metric	Ascentage Pharma Group International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.83B	$3.32B	$6.22B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	N/A	18.05	20.38	25.28
Price / Sales	3.18	284.22	542.54	73.29
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	9.59	6.73	9.81	6.91
Net Income	-$177.71M	$24.11M	$3.56B	$333.88M
7 Day Performance	-9.00%	4.11%	0.43%	0.16%
1 Month Performance	-27.94%	-2.89%	-0.87%	1.90%
1 Year Performance	-13.28%	69.06%	36.28%	32.84%

Ascentage Pharma Group International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AAPG Ascentage Pharma Group International	4.471 of 5 stars	$19.57 -3.0%	$46.67 +138.5%	-13.7%	$1.83B	$574.12M	N/A	600	Gap Down High Trading Volume
PCVX Vaxcyte	2.9055 of 5 stars	$53.01 flat	$86.00 +62.2%	+82.0%	$7.65B	N/A	N/A	160	Options Volume
KYMR Kymera Therapeutics	2.3614 of 5 stars	$86.08 flat	$118.10 +37.2%	+184.0%	$7.08B	$39.21M	N/A	170
QGEN Qiagen	4.5567 of 5 stars	$33.05 +0.0%	$46.38 +40.3%	-23.3%	$6.81B	$2.09B	17.26	5,654	Dividend Increase Analyst Downgrade Gap Up
TGTX TG Therapeutics	4.2736 of 5 stars	$42.86 flat	$52.50 +22.5%	+22.1%	$6.56B	$616.29M	14.99	290

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. PCVX, KYMR, QGEN, TGTX, and MIRM

How does Ascentage Pharma Group International compare to Vaxcyte?

Summary

How does Ascentage Pharma Group International compare to Kymera Therapeutics?

Summary

How does Ascentage Pharma Group International compare to Qiagen?

Summary

How does Ascentage Pharma Group International compare to TG Therapeutics?

Summary

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascentage Pharma Group International (AAPG) Competitors

AAPG vs. PCVX, KYMR, QGEN, TGTX, and MIRM

How does Ascentage Pharma Group International compare to Vaxcyte?

Which has more volatility & risk, PCVX or AAPG?

Do insiders & institutionals have more ownership in PCVX or AAPG?

Does the media refer more to PCVX or AAPG?

Is PCVX or AAPG more profitable?

Which has preferable valuation & earnings, PCVX or AAPG?

Do analysts rate PCVX or AAPG?

Summary

How does Ascentage Pharma Group International compare to Kymera Therapeutics?

Which has more risk & volatility, AAPG or KYMR?

Do analysts rate AAPG or KYMR?

Does the media prefer AAPG or KYMR?

Which has higher valuation and earnings, AAPG or KYMR?

Is AAPG or KYMR more profitable?

Summary

How does Ascentage Pharma Group International compare to Qiagen?

Which has more risk and volatility, AAPG or QGEN?

Do institutionals & insiders have more ownership in AAPG or QGEN?

Do analysts recommend AAPG or QGEN?

Does the media prefer AAPG or QGEN?

Which has stronger valuation & earnings, AAPG or QGEN?

Is AAPG or QGEN more profitable?

Summary

How does Ascentage Pharma Group International compare to TG Therapeutics?

Which has more volatility and risk, TGTX or AAPG?

Do insiders and institutionals have more ownership in TGTX or AAPG?

Which has preferable earnings and valuation, TGTX or AAPG?

Do analysts prefer TGTX or AAPG?

Does the media favor TGTX or AAPG?

Is TGTX or AAPG more profitable?

Summary

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Which has more volatility and risk, MIRM or AAPG?

Which has better earnings & valuation, MIRM or AAPG?

Does the media refer more to MIRM or AAPG?

Do analysts rate MIRM or AAPG?

Is MIRM or AAPG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAPG vs. The Competition

Ascentage Pharma Group International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools